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The synthesis of optically pure (R)- and (S)-2-methyl-[ 3,3,3? H3 ] alanines of 
biological interest is described. The stereochemistry of the reaction of the lithio 
derivative of (R)-(-)-2,5-dimethoxy-3-benzyl-3-methyl-3,6-dihydropyrazine with 
alkyl and deuterated alkyl iodides is discussed. The configuration of the newly 
formed center of chirality in (R)-  and (S)-2-methyl-[3,3,3? H3 1 alanines is 
derived from H NMR. 
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Amino acids optically active due to isotopic 
substitution of deuterium or I3C atoms are 
gaining increasing importance in research and 
practice as probes for biosynthesis and inter- 
conversion of various amino acids as well as 
NMR probes for peptide binding and dynamics 
(1 -3). 
Schollkopf et al. (4, 5 )  have recently re- 
ported on the enantio-selective synthesis of 
various nonproteinogenic amino acids starting 
with bis-lactim ethers of cyclo [LVal-Gly] 
and cyclo[(S) - 0,O - dimethyl - QI - methyldopa- 
Gly] . These bis-lactim ethers react with butyl- 
lithium in tetrahydrofuran at - 78°C to give 
the lithio derivatives which are condensed with 
alkyl, 2-alkenyl or 2-alkynyl halides, ketones, 
aldehydes and halomethylbenzyl ethers to form 
the appropriate adducts in high diastereomeric 
excess (> 95%). In all cases studied, the lithium 
derivative of the bis-lactim ethers containing an 
L(S) amino acid center at the C-3 is approached 
by the electrophiles trans to the bulky sub- 
stituent in the C-3 position to give the R con- 
figuration at the C-6 position. 
We have utilized these methods to prepare 
(R)- and (S)-2-methyl-[3,3,3-’ H3] alanines for 
incorporation into certain peptides in order to 
restrict their various conformational degrees of 
freedom (6) and at the same time utilize the 
deuterated methyl group in H NMR studies to 
investigate the molecular dynamics of these 
peptides and their binding to other macro- 
molecular molecules (7). 
We chose as our chiral agent (R)-(+)-2- 
methyl-3-phenylalanine 1, which was prepared 
from phenylacetone (8) in a convenient four- 
step sequence in 49% overall yield by a modified 
asymmetric Strecker synthesis first described 
by Weinger and coworkers (9). This amino acid 
was chosen because it bears an a substituent 
and therefore the cyclo [a-methylphe-gly] 
derived can be alkyhted only at the C-6 
position. The phenylalanine derivative was 
esterified with methanolic HC1 (10) and the 
resulting methyl ester 2 condensed (1 1) with N- 
t-Boc-glycine giving the dipeptide methyl ester 
3. Following the procedure of Nitecki et al. 
(12), the dipeptide methyl ester 3 was cyclized, 
579 







5 w 4 vz 
SCHEME 1 
Synthesis of (3R )-2,5 -dimethoxy-3-benzyl-3-methyl-3,6-dihydropyrazine. 
after treating with formic acid, by boilin in 
a 2:1 mixture of sec-butanol and toluene to 
yield the 2,5-diketopiperazin.e 4. The piperazine 
4 was then converted into the bis-lactim ether 5 
(see Scheme 1) by treatment with trimethyl- 
oxonium tetrafluoroborate (1 3). 
The bis-lactim ether 5 reacted directly with 
1 equiv. of butyllithium in tetrahydrofuran (or 
1,2-dimethoxyethane) at - 78OC to form the 
lithium derivative of 5 ,  a resonance-stabilized 
diazapentadienyl anion, which is regarded as an 
ion pair. This lithio derivative reacted with 
alkyl iodides to afford a mixture of diastereo- 
mers 6 and 7**. The diastereomer 6a, in which 
the alkyl group (CH,) has entered trans, with 
respect to the benzyl group at C-3, was the pre- 
dominant isomer (the ratio of truns:cis 
approach for alkylation with CH31 is 80:20 
E 
*One equivalent of morpholine was added to improve 
the cyclization, otherwise the standard Nitecki con- 
ditions gave poor yields. 
The reaction of the lithio derivative of 5 with 
methyl triflate (CH,OTf or CD,OTf) gives a 50-50 
mixture of diastereomers (6R and 6s) indicating the 
total lack of asymmetric induction. 
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(6a:7a) in THF, 85: 15 in dimethoxyethane and 
for alkylation with CD31, 78:22 (6b:7b) in 
THF, 83:17 in dimethoxyethane) and had the 
(S) configuration at the C-6 position. 
The (6s) configuration of 6a was deduced 
from the ' H  NMR spectrum. The bis-lactim 
ethers 6 and 7 adopt a boat shape for the 
heterocycle (1 3) and the folded conformation 
(14) for the benzyl group. In the 'H  NMR 
spectra, the hydrogen atom at the C-6 carbon 
of 6a appeared at 6 = 3.10, while the hydrogen 
atom of 7a appeared at 6 = 3.74. The upfield 
shift of 0.7 ppm of the 6-hydrogen is due to the 
shielding effects of the aromatic ring in the 
C-3 position (15) in 6a (compared to that in 
7a). This is consistent with the trans addition 
of the methyl group in the alkylation step, i.e., 
induction of the S configuration at C-6 in 6a. 
Additionally, the ' H  NMR spectrum of 6a 
showed a signal at 6 = 1.1 1 for the C-6 methyl, 
whereas the C-6 methyl signal in 7a appeared 
at 6 = 0.24. The upfield shift of the C-6 methyl 
in the minor diastereomer 7a (compared to that 
in 6a) is also consistent with the report of 
Woodard (1 5) and is in agreement with the 6 S  
configuration for 6a. Similarly, the 6 s  
configuration for 6b (alkylation with CD3 I) can 
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2-methyl- [3-13 C] alanines could be synthesized 
in a similar manner using unlabeled methyl- 
iodide and ["C] methyliodide. 
In conclusion, we synthesized the his-lactim 
ether (R)-(-)-2,5-dimethoxy-3-benzyl-3-methyl- 
3,6-dihydropyrazine (5) in a straightforward 
manner and utilized it as a chiral auxiliary 
reagent to prepare the title amino acids, (R)- 
and (S)-2-methyl- [3,3,3-2 H3] alanines, in enan- 
tiomeric excess of > 95%. In addition, the use 
of the dihydropyrazine (5) as a synthon 
allowed for the determination of the enantio- 
meric excess at the alkylated center directly by 
'H  NMR without the addition of chiral shift 
reagents. 
be derived from the ' H  NMR spectra of the 
hydrogen signals at the C-6. 
It is noteworthy to mention that the Rfs of 
6a and 7a (or 6 b  and 7b) are 0.73 and 0.64 
respectively in 4: 1 hexane/ethyl acetate and, 
hence, the two diastereomers 6a and 7a (or 6 b  
and 7b) are easily separable by either column 
chromatography or HPLC. The hydrolysis of 
6b and 7b would give (S)-  and (R)-[2H31- 
alanine, respectively. However, in the present 
study, the diastereomers did not need to be 
separated since the configuration at C-6 would 
be lost on lithiation in the next step. 
The mixture of monoalkylated products 6a 
and 7a was further reacted with butyllithium 
in tetrahydrofuran at -778°C to form a single 
anion (since the C-6 carbon is now sp2, there is 
no difference in the stereochemistry of the 
anions formed from 6a and 7a) which was 
attacked by [2 H3 1 methyliodide (see Scheme 2) 
to give exclusively the (3R, 6 s )  diastereomer 8a 
(% de >95% as determined by 'H  NMR). The 
second alkyl group entered trans with respect 
to the bulky benzyl group in the C-3 position. 
The (3R, 6R) diastereomer 8 b  was prepared by 
reversing the order of alkylation, i.e. ['H3]- 
methyliodide, followed by unlabeled methyl- 
iodide. The 'H NMR of both 8a and 8b showed 
only one C-6 methyl group (6 = 0.31 and 
6 = 1.10 respectively) and, hence, the di- 
astereomeric excess of both dialkylated prod- 
ucts 8a and 8b was assumed to be >95%. 
The characteristic upfield shift (0.8 ppm) of 
the 6-CH3 signal (6 = 0.31) in 8a compared to 
that (6 = 1.1) in 8b was in agreement with the 
(6s )  configuration in 8a and the (6R) con- 
figuration in 8b (1 5). 
The 3,6-dihydropyrazines 8a and 8b, on 
hydrolysis with 0.25 N HCl (4equiv.) at room 
temperature, were cleaved to give (R)-2-methyl- 
3-phenylalanine methyl ester 2 and either (S)- 
or (R)-2-methyl-[3,3,3-' H3] alanine methyl 
ester (9a or 9b), respectively. The methyl esters 
were further hydrolyzed by heating them to 
reflux in 6N hydrochloric acid to the corre- 
sponding amino acids. The target (S)- and (R)- 
2-methyl-[3,3,3-* H3] alanines (10a and lob) 
were separated by preparative thin layer 
Chromatography from the chiral auxiliary 
reagent R-(+)-2-methyl-3-phenylalanine 1, 
which could be reutilized. The (5')- and (R)- 
EXPERIMENTAL PROCEDURES 
Melting points were taken on a Mel-Temp 
capillary apparatus and are uncorrected. 
Nuclear magnetic resonance spectra were 
recorded on a Varian EM-360 60 MHz, a Bruker 
WM-360 MHz spectrometer and an IBM WP 
270 MHz spectrometer; chemical shift values 
are reported in ppni downfield from tetrame- 
thylsilane. Infrared spectra were recorded on a 
Perkin-Elmer Model 281 spectrophotometer. 
Mass spectral data were obtained on a Finnigan 
402 1 mass spectrometer (Chemistry Depart- 
ment, University of Michigan). Optical rotations 
were measured in a 1 dm cell at 25°C on a 
Perkin-Elmer Model 141 polarimeter; c is 
expressed in g/ 100 ml. 
The CD31 (99 + atom%) was purchased 
from Aldrich Chemical and used without further 
purification. 
Column chromatography was performed 
using E. Merck silica gel 60, 70-230 mesh 
ASTM, elutions being carried out with 19:l 
hexane/ethyl acetate (v:v) followed by 9: 1 
hexane/ethyl acetate unless otherwise noted. 
Analytical thin layer chromatography was per- 
formed on Analtech, 20 x 20cm plates pre- 
coated with silica gel G. Tetrahydrofuran and 
1,2-dimethoxyethane wete distilled from 
LiA1H4 immediately prior to use. Dichloro- 
methane was distilled from P205 under 
nitrogen. All organic solvent extractions were 
dried with Na2 SO4 and removed in vacuo using 
a rotary evaporator (water aspirator vacuum) 
unless otherwise stated. Elemental analyses were 
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k a  R = H  
_n 
8b hM 6 b  =X-'CH3,  Y= H (5) Mn 
MCI 7b = X =  H I  Y=CH3(R_I 
9 b  R=CH3 
?M 
l&b R = H  
SCHEME 2 
Synthesis of (2s)- and (2R)-2-methyl-[ 3,3,3-' H, J -alanine. 
performed by M-H-W Laboratories, Phoenix, 
AZ. 
(R)-(+)-N-(N-tert .-butoxycarbonyZglycinyl)2- 
methyl-3-phenylalanine methyl ester (3 ) (11 )  
To a stirred solution of (R)-(-)-2-methyl-3- 
phenylalanine methyl ester 2 (4.83 g, 25 mmol) 
in dry dichloromethane (30ml) at 0°C was 
added a solution of N-2,2-dimethylethyloxy- 
carbonylglycine (4.38 g, 25 mmol) and N,N'- 
dicyclohexylcarbodiimide (5.16 g, 25 mmol) in 
dry dichloromethane (20 ml) followed by the 
addition of 4-dimethylaminopyridine (DMAP) 
(0.61 g, 5 mmol). The reaction mixture was 
allowed to stir at 0°C for 4 h and at room tem- 
perature overnight. The urea which formed 
was removed by filtration and the filtrate 
evaporated to yield an oily residue. The residue 
was dissolved in ether (l00ml) and washed 
successively with 5% citric acid, a saturated 
NaHC03 solution, and water. The organic layer 
was evaporated to yield the crude peptide 3 as 
a viscous oil. The oily product was purified by 
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column chromatography with ethyl acetate/ 
hexane (3:2) as eluant to yield 7.2g (82.2%); 
[a} = + 45.4" (c = 1.6, methanol), H NMR 
9H, C(CH3)3), 2.98 and 3.23 (d, AB, J = 13.2 
Hz, C6H5CHz), 3.53 (dd merged into t, J = 
(DMSO-d6) 6 1.21 (s, 3H, C-CH3), 1.39 (s, 
5.82 Hz, 2H, CHzNH), 3.58 (s, 3H, COOCH,), 
6.96 (t, J = 5.55 Hz, lH,CHZNH), 7.08-7.30 
(m, 5H, C6H5 ), 7.93 (s, lH, NHCOCHz). 
Anal. calc. for C18HZ6N205: c ,  61.69; H, 
7.48. Found: C, 61.59; H, 7.49. 
(R)-(-)-3-Methyl-3-benzyl-2,5-diketopiperazine 
The procedure of Nitecki and coworkers (12) 
for converting t-Boc- pro t ec t ed dipe p tide 
methyl ester into cyclic dipeptide was modified 
as follows: the r-Boc dipeptide methyl ester 3 
(7.0g, 20.0 mmol) was dissolved in formic acid 
(125 mL) and stirred for 2 h under a drying 
tube. The solution was concentrated in vacuo 
(bath temperature < 30°C) and the residue 
triturated several times with dry ether to 
(4) 
Enantioselective synthesis of alanines 
2.0 mmol) in dry tetrahydrofuran (or better 
1,2-dimethoxyethane) (5 mL) under nitrogen at 
- 78°C was added by syringe a 1.6N solution 
(1.4 mL, 2.2 mmol) of butyllithium in hexane 
and the mixture stirred for 30-45 min to 
insure formation of the anion. Then a pre- 
cooled solution of methyl iodide (310mg, 
2.2 mmol) in dry THF (5 mL) was added and 
stirring continued for 8 h  at -78°C. The 
mixture was allowed to warm to room tempera- 
ture and the solvent removed in vacuo to give 
a residue which was dissolved in diethyl ether 
and washed with Na phosphate buffer, pH 
= 7 (3 x 25mL). After evaporation of the 
solvent, the residual product, 430 mg (82.6%), 
a mixture of 6a: 7a in the ratio of 80:20 (trans: 
cis approach) in THF and 85: 15 in dimethoxy- 
ethane, was purified by column chromato- 
graphy to yield 6a as an oil; IR (film) 1695 
cm-' (C=N) ,  ' H  NMR (DMSO-d6) 6 1.11 
C-CH3), 2.71 and 3.05 (d, AB, J = 12.75 Hz, 
(d, J ~ 7 . 1 8  Hz, 3H, 6-CH3), 1.42 (s, 3H, 
2H, CgHsCHz), 3.10 (q, J = 7 . 2 4  Hz, lH, 
6-H), 3.60 (s, 3H, ocH3), 3.62 (s, 3H, ocH3),  
6.93-7.24 (m, 5H, C6H5CH2). 
Anal. calc. for C15HZONZ02: C, 69.20; H, 
7.74. Found: C, 69.41; H, 7.85. 
precipitate the formate salt (5.1 g, 86.1%) 
which was used without further purification. 
To a solution of the formate salt in sec-butanol 
(200 mL) and toluene (100 mL) was added 
1.5 g (17.2mmol) of morpholine" and the 
whole mixture heated at reflux (96°C) for 2f h. 
After most of the solvent was removed, the 
solution was cooled to 0°C and the resulting 
solid filtered. The crude product was purified 
by recrystallization from methanol to give 2.8 g 
(64.1%) of the title compound, nip 302-304"C, 
[a] D = - 92.7" (C = 0.1 1, DMF), IR (KBr) 
1675cm-' (NHC=O), ' H  NMR (DMSO- 
d6)  6 1.41 (s, 3H, C-CH3), 2.51 and 3.34 (d, 
AB, J = 17.46Hz, 2H, CH2), 2.67 and 3.07 
(d, AB, J = 13.02 Hz, CgHsCH2), 7.12-7.28 
(m, SH, CgH5CHz), 7.79 (bs, IH, 4-NH), 
8.25 (bs, IH, 1-NH). 
Anal. calc. for Clz H14N2 O2 : C, 66.04; H, 6.47. 
Found: C, 66.04; H, 6.47. 
(R)-(--)-2,5-Dimethoxy-3- benzyl-3methyl- 
3,6-dihydropyrazine (5) 
A mixture of the diketopiperazine 4 (4.37g, 
20mmol) and 7.4g (50mmol) of trimethyl- 
oxonium tetrafluoroborate in l 0 0 m L  of dry 
dichloromethane was vigorously (mechanically) 
stirred at 40°C for 72 h. The reaction mixture 
was cooled to room te erature and a solution 
of 6 g  of potassium carbdnate in 25mL of 
water added, the organic layer separated and 
the aqueous layer extracted with dichloro- 
methane (3 x 50mL). The combined organic 
extracts were evaporated to give a crude! residue 
which was purified by column chromatography 
to yield 3.6g (73%) of 5 as an oil, [a] D = 
- 192.3" (c = 0.555, ethanol), IR (film) 1695 
cm-' (C=N) ,  ' H  NMR @MS@dg) 6 1.42 
(s, 3H, C-CH3), 2.71 and 3.03 (d, AB, J = 
12.77 Hz, 2H, c6HscH2) ,  2.84 and 3.66 (d, 
O W 3 ) ,  3.63 (s, 3H, OCH3), 6.96-7.22 (m, 
Anal. calc. for CI4Hl8NZ02 : C, 68.27; H, 7.37. 
Found: C, 68.42; H, 7.28. 
(3 R , 6 S )  2,5-Dim ethoxy-3- benzy l-3,6-dim ethyl- 
3,6-dihydropyrazine (6a) 
To a stirred solution of bis-lactim ether 5 (0.5 g, 
AB, J = 2 0 . 5 3  Hz, 2H, 6-H), 3.61 (s, 3H, 
5H, C6H5 CH2 ). 
*See footnote on page 580. 
(3R, 6 R)-2,5-Dimethoxy-3-benzyl-3,6- 
dirnethyl-3,6-dihydrupyrazine (7a) 
The title compound was obtained from the 
above reaction mixture as the minor isomer in 
10% yield as an oil; IR (film) 1695 cm-' (C 
= N), ' H  NMR (DMSO-d6)6 0.24 (d, J = 7.18 
Hz, 3H, 6-CH3), 1.42 (s, 3H, C-CH3), 2.71 and 
3.60 (s, 3H, OCH3), 3.63 (s, 3H, OCH3), 
3.74 (4, J = 7.24 Hz, lH, 6-H), 6.93-7.24 (m, 
3.05 (d, AB, J = 12.75 Hz, 2H, C ~ H S C H ~ ) ,  
SH, c6H5 CH.;). 
(3R, 6S)-2,5-Dimethoxy-3-benzyl-3-methyl-6- 
[ 2H,] methyl-3,6-dihydrupyrazine (6b) 
The bis-lactim ether 5 (0.5 g, 2.0mmol) was 
treated with [2 H3] -methyl iodide (320 mg, 
2.2 mmol) in the same way as described above 
for 6a. Purification by column chromatography 
yielded 70% (365mg) of 6b. IR (film) 1697 
cm-' (C = N), H NMR (DMSO-d6)6 1.42 
(s, 3H, C-CH3), 2.71 and 3.05 (d, AB, J 
= 12.73 HZ, 2H, CgHsCH2), 3.08 (S, IH,  
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6-H), 3.60 (s, 3H, OCH,), 3.62 (s, 3H, OCH3), 
Anal. calc. for C1~Hl7D3N202:  C, 69.20; H, 
7.74. Found: C, 68.95; H, 7.96. 
6.93-7.24 (m, SH, CgH5 CH2). 
(3R, 6R)-2,j-Dimethoxy-3-benzyl-3-methyl-6- 
[2H3 ] methyl-3,6-dihydropyrazine (7b) 
The title compound was obtained from the 
above reaction mixture as the minor isomer in 
10% yield as an oil; IR (film) 1695 cm-' (C = 
N), H NMR (DMSO-d6) 6 1.42 (s, 3H, C-CH3), 
2.71 and 3.05 (d, AB, J = 12.73 Hz, 2H, c6- 
H5CH2), 3.60 (s, 3H, OCH,), 3.77 (s, lH, 6-H), 
3.62 (s, 3H, OCH3), 6.93-7.24 (m, SH, Cg- 
HS CHz 1. 
(3R, 6S)-2,5-Dimethoxy-3- benzyl-3,6- 
dimethyl-4- [2H3]  -methyl-3,6-dihydropyrazine 
The dlhydropyrazine 6a or a mixture of 6a 
and 7a (520 mg, 2.0 mmol) in dry tetrahydro- 
furan (5mL) was alkylated under standard 
conditions (BuLi, CD31/THF, - 78"C, 8 h) 
to give the dialkylated product 8a in 74% yield 
(410 mg) after column chromatography. [a] 
= - 137.3" (c = 0.50, ethanol), %de > 95%, 
IR (film) 1697cm-' (C=N) ,  ' H  NMR 
3H, C-CH3), 2.68 and 3.058 (d, AB, J = 12.57 
Hz, 2H, CgHsCH2), 3.59 (s, 3H, OCH3), 
@a> 
(DMSO-dg) 6 0.31 (s, 3H, 6-CH3), 1.42 (s, 
3.62 (s, 3H, OCH3), '6.95-7.22 (m, 5H, c g -  
H5 CHZ 1. 
Anal. calc. for CI6Hl9D3N202: C, 70.04; H, 
8.08. Found: C, 69.83; H, 8.04. 
(3R, 6R)-2,5-Dimethoxy-3-benzyl-3,6-dimethyl 
-6- ['H3] -methyl-3,6-dihydropyrazine (8b) 
The product 8b was prepared in 76% yield from 
0.52g (2.0mmol) of 6b (or a mixture of 6b 
and 7b) and 0.3 1 g (2.2 mmol) of methyl iodide 
following the procedure described above and 
purified by column chromatography. [a] D 
= - 137.3" (c = 0.54, ethanol), %de > 9576, 
IR (film) 1698cm-' (C=N) ,  'H  NMR 
3H, C-CH,), 2.68 and 3.08 (d, AB, J = 12.57 
(s, 3H, OCH3), 6.95-7.22 (m, SH, C6H5CH2). 
Anal. calc. for C16H19D3N202: C, 70.04; H, 
8.08. Found: C, 70.13; H, 8.12 
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(DMSO-d6)6 1.10 (s, 3H, 6-CH3), 1.42 (s, 
HZ, 2H, C ~ H S C H ~ ) ,  3.59 (S, 3H, OCH3), 3.61 
(S) -2-Methyl-[ 3,3,3- H3/ alan ine (1 Oa) 
A mixture of compound 8a (550 mg, 2 mmol) 
and 16mL of 0.25N hydrochloric acid (4 
mmol) was stirred at room temperature for 
48 h. The solution was extracted with diethyl 
ether (2 x 25mL), the ether layer discarded 
and the aqueous layer concentrated to dry- 
ness in vacuo. A 6N HCI solution (5mL) was 
added and the mixture heated to reflux for 
1 h. After cooling, the solution was loaded 
onto a column containing Dowex SOW x 8 
(H30+ form) and the column eluted with water 
until the eluant was neutral followed by 
l 0 0 m L  of 1N NH4OH. Concentration of the 
ninhydrin-positive fractions of the ammoniacal 
eluate yielded a crude mixture of 1 (Rf = 0.68) 
and 10a, which was separated by preparative 
thin layer chromatography (silica gel, 2- 
propanol/ammonia/water, 20:3: 1). The (S)- 
2-meth~l-[3,3,3-~ H3] alanine (Rf = 0.32) was 
recrystallized from methanol: mp > 325°C (Lit 
(16) mp 319-320°C for the nondeuterated 
analog); yield, l lOmg (51.8%), [a],, = 0 (c 
CH3); MS (relative intensity), m/e 107(MH+, 
3), 61 (IOO), 45 (36), 44 (51), 42 (41), 28 
~ 0 . 5 ,  HzO), 'H NMR (Dz0)6 1.30 (s, 3H, 
(33) 98.66% d3. 
(R)-2-Meth~l-[3,3,3-~H~/ alanine (1 Ob) 
The 3,Qdihydropyrazine 8b (0.28 g, 1 mmol) 
was hydrolyzed to a mixture of amino acids 1 
and lob, which was separated by preparative 
thin layer chromatography as described for 10a. 
The title compound (Rf = 0.32) after recrystal- 
lization from methanol, melted at 320-323°C 
(dec)(Lit (16) mp 319-320°C for the non- 
deuterated analog); yield 0.06 g (56.5%), 
[a] D = 0 (C = 0.5, Hz 0), H NMR (Dz 0)6  
1.30 (s, 3H, CH3); MS (relative intensity), m/e 
107(MH+, 16), 61 (IOO), 45 (12), 42 (11) 
98.68% d3. 
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